26.02.2018Selexis SA and Xencor sign 4 Commercial License AgreementsYou are hereNewsSelexis SA and Xencor sign 4 Commercial License Agreements
Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, today announced that it has signed four commercial license agreements (CLAs) with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The CLAs extend the companies’ previous agreement through which Selexis is providing Xencor with access to its SUREtechnology Platform™, as well as cell line development-related services that include personnel, laboratory equipment and laboratory space.Complete press release
4à6 de BioAlps - Ferring29.05.2018Les "4à6" de BioAlps sont une série d'événements organisés dans chacun des 7 cantons de Suisse occidentale.
Kinntek chooses PryvKinntek, announces that it has chosen Pryv to extend its breakthrough hand rehabilitation interactive platform with...
Pharmasys CH - SuisseProfessional Services & Consulting, IT Services / Information Provider
Pharmasys founded in 2005 is a growing consultant company for healthcare industry with office in France, Belgium and Switzerland.
Professional Services & Consulting, Quality
Our goal is to provide customized consulting services in Engineering, Quality, Data Integrity and GxP Compliance of automated and computerized systems in the regulated health care sector: pharmaceutical, cosmetics, medical devices.
Our interventions rely on years of experience methods based rigorously on ISPE guidelines (e.g. GAMP 5). Those methods allow us to respond pragmatically to any regulatory compliance: FDA, 21 CFR Part 11, EU Chapter 4 Annex 11, cGMP's, GMP, GLP, GDP, GCP, 21 CFR Part 820, CE Mark, ISO 13485, ISO 14971, IEC 62304
Pharmasys Group provides expertise in the implementation of demanding projects and the validation of complex system as well as training staff with the latest market standards.